Company intelligence / Profile preview

Rocon

Suzhou, Jiangsu, Chinarocon.com ↗

Ownership: Private
Development stage: Other

Overview

RocRock Biotechnology has developed four core technology platforms to address challenges in macrophage research and application. These include overcoming difficulties in vitro culture expansion, long culture cycles, high costs, and gene transduction issues. The company aims to enable new clinical applications for engineered macrophages in anti-tumor therapies. No published clinical results as of June 2025.

Therapeutic areas: Oncology
Modalities: Cell therapyGene editingBiologic
Industry: Biotech

Beyond the preview

Go deeper on Rocon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rocon.

Explore the full profile